Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences
Published
Oct 11 2021 at 11:13 AM GMT
Key
Points
Points
- Tampa, Fla.-based Pacira BioSciences Inc said Monday it is acquiring Flexion Therapeutics Inc.
- , based in Burlington, Mass., for $8 a share in cash, plus a non-tradeable contingent value right (CVR) worth up to $8.50 a share in cash, in a deal aimed at expanding its position in non-opioid pain management.
- The CVR is payable based on the company meeting certain sales and regulatory milestones.
- Flexion's lead product, ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) is the first and only FDA-approved treatment for osteoarthritis knee pain using extended-release microsphere technology, the companies said in a joint statement.
- It also offering non-opioid treatments for musculoskeletal conditions, including postsurgical pain and low back pain.
Trending
Stats
- Published Oct 11, 2021 11:13 AM GMT